CCRL2 and prostate cancer: CCRL2 expression has been reported across a range of malignancies and tumor-derived cell lines, including human glioblastoma [21], colorectal carcinoma [22], breast cancer [23], prostate cancer [24], and non-small-cell lung cancer [20,25,26].